Idera Pharmaceuticals Inc.

Dr. Sullivan joined the Company in 2002 as Senior Director, Preclinical Drug Development. His prior professional experience includes a variety of technical management roles with pharmaceutical companies (Purdue Pharma, Adria), contract research organizations (Oread, Battelle, Roma Toxicology Centre), and in veterinary medicine (International Minerals & Chemical). Dr. Sullivan brings broad expertise in the design, execution, and application of nonclinical drug development programs. His publications, presentations, and reports submitted to regulatory authorities have covered topics in preclinical models of efficacy, safety pharmacology, pharmacokinetics/ADME, carcinogenicity, mutagenicity, and reproductive toxicology as well as general toxicology/pathology. Dr. Sullivan earned his B.S. in Microbiology from Michigan State University in 1975. His graduate studies were at Purdue University, where he earned a M.S. degree in Health Physics in 1978 and a Ph.D. in Toxicology in 1981.

Dr. Lough joined the Company in 2005 as Director of Business Development. Prior to joining the Company, Dr. Lough served for eight years in a variety of scientific and management positions with Sequenom, Inc., including Manager of East Coast Operations. He previously served as a technology analyst with the translational drug development company Acretia, Inc., and as a principal scientist with with the chemical genomics company NeoGenesis Pharmaceuticals, Inc (now Schering-Plough). Dr. Lough earned his B.Sc. (Hons) in Environmental Chemistry in 1991 and Ph.D. in Oligonucleotide Chemistry from the University of Edinburgh, Scotland in 1996, and earned a Graduate Certificate in Intellectual Property from Northeastern University in 2004. Dr. Lough holds seven issued U.S. Patents in the field of nucleic acids technology.

Prior to this, Dr. Taunton-Rigby was President and Chief Executive Officer of Aquila Biopharmaceuticals, Inc., a public life sciences company that was merged in late 2000 with Antigenics Inc. She was also President and Chief Executive Officer of Cambridge Biotech Corporation, where she led the turnaround, restructuring and emergence from bankruptcy. In addition, she has served as President and Chief Executive Officer of Mitotix Inc., now merged with GPC Biotech. Previous to this position, she was Senior Vice President, Biotherapeutics, at Genzyme Corporation, where she had overall responsibility for Genzyme's biotherapeutics division. Dr. Taunton-Rigby has also served in senior management positions at Vivotech Inc., Biogen, Inc. and Collaborative Research, Inc.

Mr. Hartley, age 66, has been President of Hartley Capital Advisors, a financial consulting firm, since June 2000. Mr. Hartley was Managing Partner of Forum Capital Markets LLC, an investment banking firm, from August 1995 to May 2000. Mr. Hartley also serves as a director of Universal Display Corporation, a developer of flat panel displays.

Now retired, Mr. Reardon, who holds an MBA from Harvard Business School and is a certified public accountant (CPA), was Partner at PricewaterhouseCoopers (PWC) where he led the Life Science Industry Practice for New England and the Eastern United States. His responsibilities at PWC included supervising teams conducting client audits and serving as a Securities and Exchange Commission (SEC) Consulting Partner, which required him to work closely with SEC staff. Throughout his career, Mr. Reardon has been a highly visible member of the life sciences community, a frequent speaker at industry conferences, and an active member of the Biotechnology Industry Organization (BIO) and the Massachusetts Biotechnology Council (MBC). Mr. Reardon currently serves on the boards of directors at Idera Pharmaceuticals, Inc. and Synta Pharmaceuticals, Inc.